|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Buprenorphine
|
|
gptkbp:approves
|
gptkb:2002
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Subutex
|
|
gptkbp:can_be_used_with
|
counseling
psychosocial support
|
|
gptkbp:caused_by
|
dependence
|
|
gptkbp:clinical_trial
|
conducted
|
|
gptkbp:consequences
|
exists
|
|
gptkbp:contraindication
|
respiratory depression
severe liver impairment
|
|
gptkbp:discipline
|
possible
|
|
gptkbp:discontinued
|
some markets
|
|
gptkbp:dosage_form
|
sublingual
|
|
gptkbp:duration
|
varies by patient
|
|
gptkbp:education
|
important
|
|
gptkbp:environmental_impact
|
low to moderate
|
|
gptkbp:form
|
sublingual tablet
|
|
gptkbp:has_ability
|
2mg, 8mg
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Subutex
|
|
gptkbp:ingredients
|
gptkb:buprenorphine
|
|
gptkbp:interacts_with
|
CY P3 A4 inducers
CY P3 A4 inhibitors
|
|
gptkbp:introduced
|
early 2000s
|
|
gptkbp:is_available_on
|
generic medication
|
|
gptkbp:is_considered
|
gptkb:Person
acute pain management
non-opioid users
|
|
gptkbp:is_effective_against
|
high in opioid dependence
|
|
gptkbp:is_monitored_by
|
liver function
during treatment
|
|
gptkbp:is_used_for
|
opioid dependence
|
|
gptkbp:legal_issue
|
controlled substance
|
|
gptkbp:manager
|
sublingual
|
|
gptkbp:manufacturer
|
gptkb:Reckitt_Benckiser
|
|
gptkbp:marketed_as
|
gptkb:buprenorphine
|
|
gptkbp:population
|
adults
|
|
gptkbp:related_to
|
gptkb:naloxone
methadone
|
|
gptkbp:release_region
|
many countries
|
|
gptkbp:requires
|
gptkb:theorem
|
|
gptkbp:scholarships
|
gptkb:stock_market_index
|
|
gptkbp:side_effect
|
dizziness
headache
nausea
constipation
sweating
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:suitable_for
|
pregnant women
breastfeeding women
|
|
gptkbp:symptoms
|
can occur
|
|
gptkbp:treatment
|
improved quality of life
reduce cravings
medication-assisted treatment
|
|
gptkbp:used_in
|
opioid substitution therapy
|